The Cost-Effectiveness of Beta Lactamase Inhibitors

It would be our first vli to inhibit metallobatal actumases which is quite important it is being developed currently or considered as a standalone beta lactumase inhibitor. It has a long half-life so that's good because it would facilitate use with different dosing strategies and multiple beta lactams in order to optimize that beta lactamase inhibitor exposure all right. Our next late-breaker study came to us from our friends up in western Canada and this was one of those studies that I think we all kind of know what the results are going to be but it's really nice to have an unwriting to take to like your c-suite if this is a problem

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app